AB-506 is an orally active inhibitor targeting the hepatitis B virus (HBV) core protein to suppress HBV replication; it binds to the HBV core protein, accelerates capsid assembly, and inhibits packaging of HBV pregenomic RNA (pgRNA); it is used in research on chronic hepatitis B (CHB).